PeptiMimesis, a Strasbourg, France-based biopharma company dedicated to the discovery and development of therapeutic transmembrane peptides, raised €700k ($740k) in the second seed funding tranche.
Regional seed fund Cap Innov’Est made the investment, which will be complemented with non-dilutive funding to reach more than €1M ($1.05M).
The company will use the funds to to further advance its transmembrane peptide pipeline.
Created in October 2015 and led by Marjorie Sidhoum, president, PeptiMimesis is a biopharmaceutical company dedicated to the discovery and development of transmembrane therapeutic peptides. The company’s proprietary platform delivers a set of drug candidates that act on validated targets in the field of immuno-oncology and oncology.
In is now advancing its pipeline toward an HER2-candidate nomination for breast cancer-derived brain metastasis.